Back

Smart Patients, Clinical Care Options, LLC (dba Decera Clinical Education)

  • Carcinoma, Non-Small-Cell Lung
  • Immunotherapy

Biomarker-Guided Immunotherapy Decisions in Early-Stage NSCLC

Treatment of earlystage nonsmallcell lung cancer NSCLC continues to evolve with biomarkerguided treatment selection and expanding neoadjuvant adjuvant and perioperative immunotherapy options This text module examines the role of comprehensive biomarker testing practical challenges that may delay testing and treatment decisions and evidence from pivotal phase III trials to guide the selection and sequencing of immunotherapy for patients with resectable NSCLC

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

IPCE CreditsUp to 0.5 creditsAAPA Category 1 Credit™Up to 0.5 creditsAMA PRA Category 1 Credit™Up to 0.5 creditsNursingUp to 0.5 creditsPharmacyUp to 0.5 credits

MOC types

ABIM — Medical KnowledgeUp to 0.5 points

FDA REMS

No

Qualifies for MIPS

Yes

Pricing

Free

Reported to ACCME by the provider

  • On-demand / recorded video
  • includes Online course / module
  • Credit · Up to 0.5 credits
  • MOC · Up to 0.5 points
  • Commercial Support
  • Released
    Oct 8, 2026
  • Last day to claim credit
    Apr 8, 2027 6 months left